Key Opinion Leader: Dr. Matin Reck's Impact on Oncology

Key Opinion Leader: Dr. Matin Reck's Impact on Oncology

Maria Amorosso

March 12, 2021

No items found.

Who is Dr. Martin Reck? 

Dr. Martin Reck is a leading healthcare professional whose specialty is oncology, specifically lung cancer and mesothelioma. According to the European Society for Medical Oncology, “Prof. Reck is Head of the Department of Thoracic Oncology as well as Head of the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf. Furthermore, he is PI in the German center for lung research (DZL) in the area of lung cancer.” He is frequently a Principal Investigator (PI) in a number of clinical trials, meaning that he is the lead researcher, and has been doing so for the past 27 years of his impressive tenure. 

What is his specialty? 

Dr. Reck specializes in internal medicine, as well as pulmonology. According to ESMO, “his main interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive markers.” According to his H1 profile, his specialties are Medical Oncology and Clinical Pathology. 

What work is he currently doing? 

Currently, Dr. Reck is the Department Head of Thoracic Oncology at LungenClinic Grosshansdorf, which is located in Hamburg, Germany. 

Social Media Presence 

Dr. Reck enjoys a broad social media presence, with 196 followers on Twitter and over 500 connections on LinkedIn. Due to the breadth of his work and studies, he has had 6,700 social media mentions stemming from the span of his career.

What is his research background? 

Dr. Reck has co-authored a total of 740 publications throughout the span of his tenure thus far. He has participated in 50 clinical trials. Dr. Reck helped lead the Impower 150 study, which, according to the website OncLive, investigated the impact of “the combination of atezolizumab (Tecentriq), bevacizumab (Avastin), and chemotherapy in the first-line treatment of patients with nonsquamous non—small-cell lung cancer (NSCLC).” This study was a randomized study which showed that the combination of the drugs made a significant difference in the patients’ recoveries. 

H1 acknowledges and commemorates Dr. Martin Reck’s hard work in oncology and the impact that his research has had on patients across the globe. We eagerly look forward to seeing more of his work in the thoracic oncology space, his valuable perspective in the medical field, and his positive contributions to society. 



Request Demo

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.